Donate Subscribe

Thank You!

Multimedia

May 20, 2021

The Effect of H.R. 3 on Drug Prices and Innovation

Christopher Holt

AAF’s Director of Health Care Policy Christopher Holt explains why Democrats’ proposed drug-pricing legislation, H.R. 3, will restrict drug availability and innovation.

Disclaimer

Christopher Holt

Vice President of Policy and Federal Affairs at the Alliance for Health Policy

Christopher Holt is the Vice President of Policy and Federal Affairs at the Alliance for Health Policy. He previously served as Director of Health Care Policy at the American Action Forum. 

Recent Posts

April 12, 2024

Multimedia

Reforming the TCJA – CNBC

Douglas Holtz-Eakin

AAF President Douglas Holtz-Eakin discusses his and Kevin Brady's WSJ op-ed on the TCJA and future reforms on CNBC. Expiring 2017 Trump Tax Cuts Create…

April 11, 2024

Multimedia

The AAF Exchange — Ep. 145: Taxes and Regulations

Douglas Holtz-Eakin, Dan Goldbeck

On today's episode: Tax claims, misstatements, confusion...and a regulatory “win”? Joining us to discuss is AAF President Douglas Holtz-Eakin and AAF…

April 5, 2024

Multimedia

March Jobs Report – MSNBC

Douglas Holtz-Eakin

AAF President Douglas Holtz-Eakin discusses the latest jobs report on MSNBC.

March 28, 2024

Multimedia

The AAF Exchange — Ep. 144: United States v. Apple

Jeffrey Westling

AAF Director of Technology and Innovation Policy Jeff Westling joins us for a deep dive into the Department of Justice's antitrust lawsuit against Apple…

Appears in:

The Drug Pricing Clinic

Christopher Holt

Vice President of Policy and Federal Affairs at the Alliance for Health Policy

Christopher Holt is the Vice President of Policy and Federal Affairs at the Alliance for Health Policy. He previously served as Director of Health Care Policy at the American Action Forum. 

The American Action Forum is a 21st century center-right policy institute providing actionable research and analysis to solve America’s most pressing policy challenges.